Source comparison
Pulsatile vs Bolus Protocols: Matching Dosing Strategy to Research Goals
Single IV bolus administration (0.24–1.0 nmol/kg) produces a single LH pulse peaking at 60–90 minutes post-injection, followed by return to baseline within 3–4 hours. This mimics the endogenous LH surge seen at ovulation but does not replicate the pulsatile LH
This comparison does not assign a generated winner or score.
- Single IV bolus administration (0.24–1.0 nmol/kg) produces a single LH pulse peaking at 60–90 minutes post-injection, followed by return to baseline within 3–4 hours. This mimics the endogenous LH surge seen at ovulation but does not replicate the pulsatile LH secretion pattern that governs baseline reproductive function. Bolus protocols are ideal for acute stimulation studies, proof-of-concept trials, or diagnostic applications assessing pituitary responsiveness.
- Pulsatile infusion protocols. Delivering 0.1–0.3 nmol/kg every 60–90 minutes via programmable pump. Sustain LH pulsatility over 6–24 hours without causing GnRH receptor downregulation, the phenomenon that limits continuous kisspeptin efficacy. Continuous high-dose infusion (≥1.0 nmol/kg/hour) paradoxically suppresses LH after 4–6 hours because sustained GnRH receptor occupancy triggers internalisation and desensitisation at the pituitary gonadotrope level. This is the same mechanism exploited by GnRH agonist medications (leuprolide, goserelin) to achieve chemical castration. Chronic overstimulation shuts down the axis.
- Research from Massachusetts General Hospital published in 2022 demonstrated that pulsatile kisspeptin at 0.2 nmol/kg every 75 minutes maintained physiological LH pulse frequency (one pulse every 60–90 minutes) for up to 12 hours in healthy men, whereas continuous infusion at the same cumulative dose suppressed LH to hypogonadal levels by hour 8. The dosing interval matters as much as the dose itself when the goal is sustained gonadotropin drive rather than acute stimulation.